Kathleen M Doherty1, Theresa A Scott2, Anna Morad3, Travis Crook3, Elizabeth McNeer2,4, Kim S Lovell2, James C Gay3, Stephen W Patrick3,2. 1. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee; kathleen.doherty@vumc.org. 2. Vanderbilt Center for Child Health Policy, Nashville, Tennessee; and. 3. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee. 4. Department of Biostatistics, School of Medicine, Vanderbilt University, Nashville, Tennessee.
Abstract
BACKGROUND AND OBJECTIVES: National estimates indicate that the incidence of neonatal abstinence syndrome (NAS), a postnatal opioid withdrawal syndrome, increased more than fivefold between 2004 and 2016. There is no gold standard definition for capturing NAS across clinical, research, and public health settings. Our objective was to evaluate how different definitions of NAS modify the calculated incidence when applied to a known population of opioid-exposed infants. METHODS: Data for this retrospective cohort study were obtained from opioid-exposed infants born at Vanderbilt University Medical Center in 2018. Six commonly used clinical and surveillance definitions of opioid exposure and NAS were applied to the study population and evaluated for accuracy in assessing clinical withdrawal. RESULTS: A total of 121 opioid-exposed infants met the criteria for inclusion in our study. The proportion of infants who met criteria for NAS varied by predefined definition, ranging from 17.4% for infants who received morphine to 52.8% for infants with the diagnostic code for opioid exposure. Twenty-eight infants (23.1%) received a clinical diagnosis of NAS by a medical provider, and 38 (34.1%) received the diagnostic code for NAS at discharge. CONCLUSIONS: We found significant variability in the incidence of opioid exposure and NAS among a single-center population using 6 common definitions. Our findings suggest a need to develop a gold standard definition to be used across clinical, research, and public health surveillance settings.
BACKGROUND AND OBJECTIVES: National estimates indicate that the incidence of neonatal abstinence syndrome (NAS), a postnatal opioid withdrawal syndrome, increased more than fivefold between 2004 and 2016. There is no gold standard definition for capturing NAS across clinical, research, and public health settings. Our objective was to evaluate how different definitions of NAS modify the calculated incidence when applied to a known population of opioid-exposed infants. METHODS: Data for this retrospective cohort study were obtained from opioid-exposed infants born at Vanderbilt University Medical Center in 2018. Six commonly used clinical and surveillance definitions of opioid exposure and NAS were applied to the study population and evaluated for accuracy in assessing clinical withdrawal. RESULTS: A total of 121 opioid-exposed infants met the criteria for inclusion in our study. The proportion of infants who met criteria for NAS varied by predefined definition, ranging from 17.4% for infants who received morphine to 52.8% for infants with the diagnostic code for opioid exposure. Twenty-eight infants (23.1%) received a clinical diagnosis of NAS by a medical provider, and 38 (34.1%) received the diagnostic code for NAS at discharge. CONCLUSIONS: We found significant variability in the incidence of opioid exposure and NAS among a single-center population using 6 common definitions. Our findings suggest a need to develop a gold standard definition to be used across clinical, research, and public health surveillance settings.
Authors: Faouzi I Maalouf; William O Cooper; Shannon M Stratton; Judith A Dudley; Jean Ko; Anamika Banerji; Stephen W Patrick Journal: Pediatrics Date: 2018-12-04 Impact factor: 7.124
Authors: Travis W Crook; Erin K Munn; Theresa A Scott; Anna Morad; Joshua Wyatt; David P Johnson; Mary White; Stephen W Patrick Journal: Hosp Pediatr Date: 2019-08
Authors: Ashley A Leech; William O Cooper; Elizabeth McNeer; Theresa A Scott; Stephen W Patrick Journal: Health Aff (Millwood) Date: 2020-05 Impact factor: 6.301
Authors: Lisa M Grisham; Meryl M Stephen; Mary R Coykendall; Maureen F Kane; Jocelyn A Maurer; Mohammed Y Bader Journal: Adv Neonatal Care Date: 2019-04 Impact factor: 1.968
Authors: Jonathan M Davis; Jeffrey Shenberger; Norma Terrin; Janis L Breeze; Mark Hudak; Elisha M Wachman; Peter Marro; Erica L Oliveira; Karen Harvey-Wilkes; Adam Czynski; Barbara Engelhardt; Karen D'Apolito; Debra Bogen; Barry Lester Journal: JAMA Pediatr Date: 2018-08-01 Impact factor: 16.193
Authors: Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis Journal: JAMA Date: 2012-04-30 Impact factor: 56.272
Authors: Veeral N Tolia; Karna Murthy; Monica M Bennett; Rachel G Greenberg; Daniel K Benjamin; P Brian Smith; Reese H Clark Journal: J Pediatr Date: 2018-09-14 Impact factor: 4.406
Authors: Kristen L Benninger; Jessica Purnell; Sara Conroy; Kenneth Jackson; Nancy Batterson; Mary Lauren Neel; Mark E Hester; Nathalie L Maitre Journal: Dev Med Child Neurol Date: 2021-09-16 Impact factor: 5.449